Department of Anatomy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China.
Hepatobiliary Pancreat Dis Int. 2013 Apr;12(2):125-35. doi: 10.1016/s1499-3872(13)60021-1.
Non-alcoholic fatty liver disease (NAFLD) is a leading cause of chronic liver injury and mortality in Western countries and China. However, as to date, there is no direct and effective therapy for this disease. The aim of this review is to analyze the key progress and challenges of main current therapeutic approaches in NAFLD.
We carried out a PubMed search of English-language articles relevant to NAFLD therapy.
There are two major therapeutic strategies for NAFLD treatment: (1) lifestyle interventions (including weight reduction, dietary modification and physical exercise) and (2) pharmaceutical therapies. Lifestyle interventions, particularly chronic and moderate intensity exercise, are the most effective and recognized clinical therapies for NAFLD. For pharmaceutical therapies, although their effects and mechanisms have been extensively investigated in laboratory studies, they still need further tests and investigations in clinical human trials.
Future advancement of NAFLD therapy should focus on the mechanistic studies on cell based and animal models and human clinical trials of exercise, as well as the combination of lifestyle intervention and pharmaceutical therapy specifically targeting main signaling pathways related to lipid metabolism, oxidative stress and inflammation.
非酒精性脂肪性肝病(NAFLD)是西方国家和中国导致慢性肝损伤和死亡的主要原因。然而,迄今为止,尚无针对该病的直接有效疗法。本综述旨在分析目前 NAFLD 主要治疗方法的关键进展和挑战。
我们对与 NAFLD 治疗相关的英文文献进行了 PubMed 检索。
NAFLD 的治疗有两种主要的治疗策略:(1)生活方式干预(包括减重、饮食改变和体育锻炼)和(2)药物治疗。生活方式干预,尤其是慢性和中等强度的运动,是最有效和公认的治疗 NAFLD 的临床疗法。对于药物治疗,尽管它们的作用和机制已在实验室研究中得到广泛研究,但仍需要在临床人体试验中进一步测试和研究。
NAFLD 治疗的未来进展应侧重于细胞和动物模型的机制研究以及运动的人体临床试验,以及针对脂质代谢、氧化应激和炎症相关主要信号通路的生活方式干预和药物治疗的结合。